Abbott Spinal Cord Stimulators

The Judicial Panel on Multidistrict Litigation denied MDL consolidation for Abbott spinal cord stimulator litigation on June 5, 2026, on technical Section 1407 grounds that all then-pending cases resided in the Northern District of Illinois; plaintiffs filed a renewed centralization petition as MDL No. 3194 on approximately June 22, 2026, identifying 15 pending cases across multiple districts, with Abbott opposing and no hearing date set as of late August 2026. Individual cases proceed in federal district courts—primarily N.D. Ill.—alleging that Abbott's Proclaim, Eterna, and Infinity systems cause painful electric shocks, lead migration, battery failures, and loss of therapeutic benefit requiring revision or explant surgery. Core claims include manufacturing defect, failure to warn, negligence, and fraud, with a central theory that Abbott made over 230 post-approval modifications to firmware, battery design, and stimulation architecture under original PMA P010032 (approved 2001) without obtaining a new PMA or adequate clinical testing.

Abbott spinal cord stimulator litigation awaits JPML ruling on MDL No. 3194 following September 24, 2026 oral arguments. Abbott opposes consolidation of 23 pending cases, arguing individualized injuries defeat commonality; plaintiffs counter that shared device platforms and nerve injury patterns warrant coordination. No MDL established; cases remain individually filed across multiple districts.

No national exposure pattern identified for Abbott spinal cord stimulators from available sources. Litigation remains decentralized after JPML denied MDL centralization; 15 cases identified in June 2026 petition, expanding to 23 cases by August 2026 per Abbott opposition. No state court MDL or coordinated proceeding exists. Fresh centralization petition pending with Abbott in active opposition.

• Northern District of Illinois

  Primary federal venue for Abbott spinal cord stimulator litigation. Tuttle v. Abbott, No. 1:25-cv-15083 (N.D. Ill.) and Melby v. Abbott Laboratories (filed March 13, 2026) allege painful electric shocks, lead migration, and battery failures in Proclaim, Infinity, and Eterna systems. JPML denied MDL centralization June 5, 2026 because all four then-pending cases resided in same district, failing 28 U.S.C. § 1407's 'different districts' requirement. Fresh centralization petition filed approximately June 22, 2026 identifying 15 pending cases; Abbott opposes, no hearing set.

• Central District of California

  Abbott opposes MDL centralization to this district in August 2026 motion. Separate MDL No. 3181 for Boston Scientific spinal cord stimulator cases established here before Judge Josephine L. Staton. Abbott notes majority of plaintiffs have no connection to districts where suits filed; at least one plaintiff was implanted with non-SCS device; another filed two suits in two districts with conflicting allegations.

• District of New Jersey

  Active individual federal filing venue for Abbott spinal cord stimulator cases post-JPML denial. Cases proceed individually with parallel discovery tracks; no global settlement program announced.

• District of Hawaii

  Active individual federal filing venue for Abbott spinal cord stimulator cases post-JPML denial. Cases in early procedural phases.

Medical-device product-liability deadlines vary by state and usually run from injury, implant/explant, diagnosis, or discovery of a possible device connection. SCS cases may involve PMA preemption and FDA-related theories, so counsel should preserve device records and file-specific accrual facts early.